Krish S. Krishnan - Mar 13, 2025 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Krish S. Krishnan
Stock symbol
KRYS
Transactions as of
Mar 13, 2025
Transactions value $
-$8,889,525
Form type
4
Date filed
3/13/2025, 06:04 PM
Previous filing
Feb 28, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$193K -1.1K -0.07% $175.83 1.56M Mar 13, 2025 Direct F1, F2
transaction KRYS Common Stock Sale -$874K -4.94K -0.32% $176.80 1.55M Mar 13, 2025 Direct F1, F3
transaction KRYS Common Stock Sale -$1.94M -10.9K -0.7% $177.62 1.54M Mar 13, 2025 Direct F1, F4
transaction KRYS Common Stock Sale -$1.21M -6.77K -0.44% $178.77 1.53M Mar 13, 2025 Direct F1, F5
transaction KRYS Common Stock Sale -$226K -1.26K -0.08% $179.57 1.53M Mar 13, 2025 Direct F1, F6
transaction KRYS Common Stock Sale -$288K -1.64K -0.11% $175.97 1.49M Mar 13, 2025 By Spouse F8, F9, F10
transaction KRYS Common Stock Sale -$810K -4.58K -0.31% $176.88 1.48M Mar 13, 2025 By Spouse F8, F10, F11
transaction KRYS Common Stock Sale -$1.94M -10.9K -0.74% $177.66 1.47M Mar 13, 2025 By Spouse F8, F10, F12
transaction KRYS Common Stock Sale -$1.16M -6.51K -0.44% $178.76 1.47M Mar 13, 2025 By Spouse F8, F10, F13
transaction KRYS Common Stock Sale -$239K -1.33K -0.09% $179.55 1.46M Mar 13, 2025 By Spouse F8, F10, F14
holding KRYS Common Stock 90K Mar 13, 2025 By Krishnan Spousal Trust
holding KRYS Common Stock 50K Mar 13, 2025 By Krishnan Family Trust F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.
F2 The transaction was executed in multiple trades ranging from $175.23 to $176.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $176.28 to $177.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $177.28 to $178.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The transaction was executed in multiple trades ranging from $178.29 to $179.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The transaction was executed in multiple trades ranging from $179.29 to $179.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
F8 The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share.
F9 The transaction was executed in multiple trades ranging from $175.30 to $176.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.
F11 The transaction was executed in multiple trades ranging from $176.30 to $177.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12 The transaction was executed in multiple trades ranging from $177.30 to $178.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13 The transaction was executed in multiple trades ranging from $178.31 to $179.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14 The transaction was executed in multiple trades ranging from $179.33 to $179.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.